Profiles Header - Harvard Catalyst Profiles Header – Harvard Catalyst

Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Sherri-Ann Maryna Burnett, M.D.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone. 2017 02; 95:20-25. PMID: 27840301.
    View in: PubMed
  2. Leder BZ, Tsai JN, Burnett-Bowie SA, Bouxsein ML, Neer RM. Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics. Bone. 2016 08; 89:73-74. PMID: 27157641.
    View in: PubMed
  3. Tsai JN, Uihlein AV, Burnett-Bowie SM, Neer RM, Derrico NP, Lee H, Bouxsein ML, Leder BZ. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016 05; 101(5):2023-30. PMID: 26964731.
    View in: PubMed
  4. Finkelstein JS, Lee H, Leder BZ, Burnett-Bowie SA, Goldstein DW, Hahn CW, Hirsch SC, Linker A, Perros N, Servais AB, Taylor AP, Webb ML, Youngner JM, Yu EW. Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Invest. 2016 Mar 01; 126(3):1114-25. PMID: 26901812; PMCID: PMC4767351.
  5. Leder BZ, Tsai JN, Neer RM, Uihlein AV, Wallace PM, Burnett-Bowie SA. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. J Clin Densitom. 2016 Jul-Sep; 19(3):346-51. PMID: 26900146.
    View in: PubMed
  6. Mitchell DM, Leder BZ, Cagliero E, Mendoza N, Henao MP, Hayden DL, Finkelstein JS, Burnett-Bowie SA. Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. Am J Clin Nutr. 2015 Aug; 102(2):385-92. PMID: 26156733; PMCID: PMC4515870.
  7. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19; 386(9999):1147-55. PMID: 26144908; PMCID: PMC4620731.
  8. Tsai JN, Zhu Y, Foley K, Lee H, Burnett-Bowie SA, Neer RM, Leder BZ. Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. J Clin Endocrinol Metab. 2015 Jul; 100(7):2718-23. PMID: 25933031.
    View in: PubMed
  9. Cauley JA, Greendale GA, Ruppert K, Lian Y, Randolph JF, Lo JC, Burnett-Bowie SA, Finkelstein JS. Serum 25 hydroxyvitamin D, bone mineral density and fracture risk across the menopause. J Clin Endocrinol Metab. 2015 May; 100(5):2046-54. PMID: 25719933.
    View in: PubMed
  10. Tsai JN, Uihlein AV, Burnett-Bowie SA, Neer RM, Zhu Y, Derrico N, Lee H, Bouxsein ML, Leder BZ. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res. 2015 Jan; 30(1):39-45. PMID: 25043459.
    View in: PubMed
  11. Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014 May; 99(5):1694-700. PMID: 24517156.
    View in: PubMed
  12. Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013 12 19; 369(25):2457. PMID: 24350954.
    View in: PubMed
  13. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, Thomas BJ, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013 Sep 12; 369(11):1011-22. PMID: 24024838; PMCID: PMC4142768.
  14. Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013 Jul 06; 382(9886):50-6. PMID: 23683600; PMCID: PMC4083737.
  15. Mitchell DM, Henao MP, Finkelstein JS, Burnett-Bowie SA. Prevalence and predictors of vitamin D deficiency in healthy adults. Endocr Pract. 2012 Nov-Dec; 18(6):914-23. PMID: 22982792.
    View in: PubMed
  16. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SA, Mannstadt M. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012 Dec; 97(12):4507-14. PMID: 23043192; PMCID: PMC3513540.
  17. Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol. 2012 Apr; 7(4):624-31. PMID: 22300739.
    View in: PubMed
  18. Lo JC, Burnett-Bowie SA, Finkelstein JS. Bone and the perimenopause. Obstet Gynecol Clin North Am. 2011 Sep; 38(3):503-17. PMID: 21961717; PMCID: PMC3920744.
  19. Bell TD, Demay MB, Burnett-Bowie SA. The biology and pathology of vitamin D control in bone. J Cell Biochem. 2010 Sep 01; 111(1):7-13. PMID: 20506379; PMCID: PMC4020510.
  20. Bhan I, Burnett-Bowie SA, Ye J, Tonelli M, Thadhani R. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol. 2010 Mar; 5(3):460-7. PMID: 20185603.
    View in: PubMed
  21. Burnett-Bowie SA, McKay EA, Lee H, Leder BZ. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J Clin Endocrinol Metab. 2009 Dec; 94(12):4785-92. PMID: 19820017; PMCID: PMC2795655.
  22. Burnett-Bowie SM, Henao MP, Dere ME, Lee H, Leder BZ. Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. J Bone Miner Res. 2009 Oct; 24(10):1681-5. PMID: 19419295; PMCID: PMC2743281.
  23. Burnett-Bowie SM. Vitamin D and fat: the chicken versus the egg. Menopause. 2009 Jul-Aug; 16(4):637-8. PMID: 19546823.
    View in: PubMed
  24. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009 Aug; 94(8):2915-21. PMID: 19435827; PMCID: PMC2730878.
  25. Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, Jüppner H, Neer RM. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab. 2009 Jul; 94(7):2495-501. PMID: 19401368; PMCID: PMC2708954.
  26. Burnett-Bowie SM, Saag K, Sebba A, de Papp AE, Chen E, Rosenberg E, Greenspan SL. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. J Clin Endocrinol Metab. 2009 Apr; 94(4):1097-103. PMID: 19141590.
    View in: PubMed
  27. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2009 Jan; 70(1):116-23. PMID: 18616708.
    View in: PubMed
  28. Burnett-Bowie SM. Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture? Nat Clin Pract Endocrinol Metab. 2008 Dec; 4(12):660-1. PMID: 18981994.
    View in: PubMed
  29. Moore AF, Wexler TL, Yung RL, Kish J, Larvie M, Lauter K, Arnold A, Finkelstein JS, Burnett-Bowie SM. An unusual case of primary hyperparathyroidism with profoundly elevated parathyroid hormone levels. Endocr Pract. 2008 Oct; 14(7):892-7. PMID: 18996820.
    View in: PubMed
  30. Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone. 2007 Apr; 40(4):913-8. PMID: 17157573; PMCID: PMC2083121.
  31. Burnett SM, Gunawardene SC, Bringhurst FR, Jüppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006 Aug; 21(8):1187-96. PMID: 16869716.
    View in: PubMed
  32. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab. 2006 Aug; 91(8):2882-7. PMID: 16684825.
    View in: PubMed
  33. Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006 Jul; 91(7):2631-7. PMID: 16636120.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Burnett's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (153)
Explore
_
Co-Authors (20)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Tool Page Footer - Harvard Catalyst Tool Page Footer – Harvard Catalyst
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.